Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Brooks

Showing results (581-590 of 620) with videos related to

Pageof 62
Sort By:
Global Mental Health (Cambridge, England)|January 9, 2023
Feasibility of a school-based mental health program implementation to improve the status of depression and quality of life of mothers of children with autism spectrum disorders in urban Bangladesh: MENTHOL studyAliya Naheed, Md Saimul Islam, Meredith B Brooks, et al.
Health Services Research|January 14, 2020
Trends in smoking documentation rates in safety net clinicsStephen P Fortmann, Steffani R Bailey, Neon B Brooks, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Multiple Sclerosis and Related Disorders|May 30, 2018
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]Yara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Platelets|November 29, 2017
Endothelial alterations in a canine model of immune thrombocytopeniaDana N LeVine, Rachel E Cianciolo, Keith E Linder, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2018
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled TrialGustavo E Velásquez, Meredith B Brooks, Julia M Coit, et al.
Plos One|January 13, 2017
Non-Lethal Endotoxin Injection: A Rat Model of HypercoagulabilityMarjory B Brooks, James R Turk, Abraham Guerrero, et al.
The Journal of Infectious Diseases|April 16, 2025
Impact of pharmacogenetics on pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trialE A Mackay, G Platt, C A Peloquin, et al.
Journal of Medicinal Chemistry|May 16, 2003
Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitorsGuoxin Zhu, Scott E Conner, Xun Zhou, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitorsRima S Al-awar, James E Ray, Kyle A Hecker, et al.
Pageof 62

Showing results (581-590 of 620) with videos related to

Sort By:
Pageof 62
Global Mental Health (Cambridge, England)|January 9, 2023
Feasibility of a school-based mental health program implementation to improve the status of depression and quality of life of mothers of children with autism spectrum disorders in urban Bangladesh: MENTHOL studyAliya Naheed, Md Saimul Islam, Meredith B Brooks, et al.
Health Services Research|January 14, 2020
Trends in smoking documentation rates in safety net clinicsStephen P Fortmann, Steffani R Bailey, Neon B Brooks, et al.
Multiple Sclerosis and Related Disorders|November 29, 2017
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodYara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Multiple Sclerosis and Related Disorders|May 30, 2018
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]Yara Dadalti Fragoso, Tim Spelman, Cavit Boz, et al.
Platelets|November 29, 2017
Endothelial alterations in a canine model of immune thrombocytopeniaDana N LeVine, Rachel E Cianciolo, Keith E Linder, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2018
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled TrialGustavo E Velásquez, Meredith B Brooks, Julia M Coit, et al.
Plos One|January 13, 2017
Non-Lethal Endotoxin Injection: A Rat Model of HypercoagulabilityMarjory B Brooks, James R Turk, Abraham Guerrero, et al.
The Journal of Infectious Diseases|April 16, 2025
Impact of pharmacogenetics on pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trialE A Mackay, G Platt, C A Peloquin, et al.
Journal of Medicinal Chemistry|May 16, 2003
Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitorsGuoxin Zhu, Scott E Conner, Xun Zhou, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2004
Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitorsRima S Al-awar, James E Ray, Kyle A Hecker, et al.
Pageof 62